Resistance markers to sulfadoxine-pyrimethamine and amodiaquine in the context of seasonal malaria chemoprevention in Burkina Faso
Published:
Resources: Poster
Authors: Cheick Compaore, Craig Bonington, Kevin Baker, Paul Sondo, Adama Traore, Clotaire Tapsoba, Boulaye Dao, Ambroise Ouedraogo, Sidzabda Kompaore, Gauthier Tougri, Halidou Tinto
Sulfadoxine-pyrimethamine and amodiaquine remain effective after eight years of SMC implementation in Burkina Faso.
In 2022, 8.3 million maria cases were reported in Burkina Faso. Since 2014, seasonal malaria chemoprevention (SMC), using antimalarial medicines sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ), has been implemented. However, there are no data on molecular resistance markers for these drugs. This study assessed resistance to SP and AQ by examining specific molecular markers in blood samples from the Boussé district before and after SMC in 2022. This poster was presented at the 72nd annual meeting of the American Society of Tropical Medicine and Hygiene.
Tagged under:
Conference
American Society of Tropical Medicine and Hygiene Annual Meeting